Comparative Efficacy and Safety of Immunomodulatory Therapies for Sepsis

A systematic review and network meta-analysis of 76 randomized controlled trials involving 22,194 patients, conducted by Rong Luo and published on figshare in 2026. The study compares the safety and efficacy of various immunomodulators for sepsis, including ulinastatin, thymosin-α1, polyunsaturated fatty acids, and monoclonal antibodies.

Use Cases

• Comparing the mortality reduction efficacy of different immunomodulators based on reported risk ratios.
• Evaluating the impact of therapies on hospital and ICU length of stay based on mean difference data.
• Assessing the safety profiles of sepsis treatments based on adverse event monitoring.
• Ranking treatment interventions for sepsis based on SUCRA values from network meta-analysis.

Strengths

• Analysis is based on 76 randomized controlled trials, providing a substantial evidence base.
• Includes data on 22,194 patients, offering a large sample size for the meta-analysis.
• Uses established statistical methods (network meta-analysis, GRADE) for evidence synthesis.

Limitations

• The underlying data tables and column definitions are not provided, limiting direct data reuse.
• The certainty of evidence for most comparisons is graded as low, as noted in the conclusion.
• The primary file format is a DOCX document, which may require parsing to extract structured data.

Provenance

Source

figshare

Collection Method

Systematic review and network meta-analysis of trials from PubMed, Embase, and the Cochrane Library.

Time Range

Trials searched from database inception to March 31, 2025.

Freshness

Last updated 2026-05-12 05:42:49.